WO2006075776A1 - 慢性閉塞性肺疾患(COPD)、嚢胞性線維症(Cystic Fibrosis)または肺高血圧症(pulmonary hypertension)治療剤 - Google Patents
慢性閉塞性肺疾患(COPD)、嚢胞性線維症(Cystic Fibrosis)または肺高血圧症(pulmonary hypertension)治療剤 Download PDFInfo
- Publication number
- WO2006075776A1 WO2006075776A1 PCT/JP2006/300665 JP2006300665W WO2006075776A1 WO 2006075776 A1 WO2006075776 A1 WO 2006075776A1 JP 2006300665 W JP2006300665 W JP 2006300665W WO 2006075776 A1 WO2006075776 A1 WO 2006075776A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- decoy
- therapeutic
- agent according
- preventive
- oligonucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
Definitions
- the present invention relates to a preventive / treating / ameliorating agent for chronic obstructive pulmonary disease (C0PD), cystic fibrosis (pulmonary hypertension) or pulmonary hypertension containing NF- ⁇ decoy as an active ingredient.
- C0PD chronic obstructive pulmonary disease
- cystic fibrosis pulmonary hypertension
- pulmonary hypertension containing NF- ⁇ decoy as an active ingredient.
- C0PD is a disease characterized by obstructive ventilation disorder of the lung. Chronic smoking damages bronchial epithelial cells, triggering them to infiltrate inflammatory cells and causing inflammation in the trachea and alveoli. Mucus secretion increases, cough, and sputum appear as early symptoms of C0PD. As it progresses, airway wall thickening and inflammation breaks down alveolar support tissue, and obstructive pulmonary dysfunction and loss of elastic contractile force in the lung cause a 1 second rate (FEV1) drop. It is a disease with a poor prognosis that generally has a long course. In Japan, it is estimated that there are more than 5 million potential C0PD patients, and the number of patients is expected to increase as the population ages. Currently, bronchodilators and dalcocoltide are used to manage C0PD (Reference 4), but there is no fundamental cure. It has also been pointed out that inhaled steroids increase the risk of osteoporosis (Reference 13).
- cystic fibrosis CFTR (cystic fibrosis
- transmembrane conductance regulator Isi: c
- Isi transmembrane conductance regulator
- Pulmonary hypertension occurs later in C0PD (stage m: severe C0PD), usually after severe hypoxemia (Pa0 2 ⁇ 8. OkPa or 60 mmHg), often accompanied by C0 2 hematoma . Pulmonary hypertension is a major cardiovascular complication of C0PD, leading to the development of pulmonary heart and poor prognosis. However, even in patients with severe C0PD, pulmonary artery pressure usually rises slightly at rest, but increases significantly with effort. The progression of pulmonary hypertension in C0PD is slow even with terminal therapy.
- metaplasia is an obstructive pulmonary disease accompanied by inflammation with mucus plugs due to mucus, and the inflammatory cells involved are also monocytes, macrophages, and neutrophils. , 8, 10). Since it is difficult to repair broken bronchi and alveolar epithelial cells, effective suppression of inflammatory responses is important in treating these diseases to prevent further destruction of the cells.
- NF-B is a regulator of gene expression of various site-in, chemokines, and cell adhesion factors. Suppressing the action of NF-KB already suppresses various inflammatory and immunological reactions. Known for atopy and rheumatoid arthritis models. Regarding obstructive pulmonary disease, it has been reported that NF-KB activation occurs in a mouse model caused by cigarette smoke (Reference 6).
- Hubbard RC Fells G, Gadek J, Pacholok S, Humes J, Crystal RG.
- W0-A 03/105780 discloses a method of administering an antisense dry powder to various diseases. Disclosure of the invention
- W0-A 03/105780 does not disclose anything about the use of NF- ⁇ : ⁇ decoy. Moreover, it was not fully known what effect the suppression of the action of NF-Zi B would have. In the model of obstructive pulmonary disease using guinea pigs, the present inventors determined a base pair of about 20 bases including a DNA sequence (consensus sequence) that binds when NF- ⁇ controls gene expression. It was proved that the DNA derivative (NF- / i B decoy) possessed was effective at a low dose, and the present invention was completed.
- Decoy means “decoy” in English, and a substance that has a structure resembling that of a substance that should bind or act is called decoy.
- a decoy for a transcription factor that binds to a binding region on a genomic gene a double-stranded oligonucleotide having the same base sequence as the binding region is mainly used. In the presence of such an oligonucleotide decoy, a part of the transcription factor molecule does not bind to the binding region on the genomic gene to be originally bound, but binds to the oligonucleotide decoy.
- a consensus sequence refers to a common gene sequence to which an arbitrary transcription factor binds.
- the consensus sequence to which NF-CB binds is GGGRHTYYHC (where R is A or G, Y is C or T, H is A, C or T) (SEQ ID NO: 1).
- a sequence such as gggatttccc (SEQ ID NO: 2) or gggactttcc (SEQ ID NO: 4) can be derived based on this consensus sequence.
- the present invention comprises (1) prevention / treatment of chronic obstructive pulmonary disease (C0PD), cystic fibrosis or pulmonary hypertension, comprising NF- / ⁇ decoy as an active ingredient It is an improving agent.
- C0PD chronic obstructive pulmonary disease
- cystic fibrosis or pulmonary hypertension
- NF- / ⁇ decoy as an active ingredient
- the present invention prevents chronic obstructive pulmonary disease (C0PD), cystic fibrosis or pulmonary hypertension by administering a pharmacologically effective amount of the above NF-B decoy to a patient.
- C0PD chronic obstructive pulmonary disease
- cystic fibrosis or pulmonary hypertension by administering a pharmacologically effective amount of the above NF-B decoy to a patient.
- -Treatment If you want to change, use fe.
- the present invention provides the above-described NF-B decoy for the prevention, treatment and improvement of chronic obstructive pulmonary disease (C0PD), cystic fibrosis or pulmonary hypertension. This is the application to be used. Detailed Description of the Invention
- the present invention includes the following as preferred embodiments.
- NF- ⁇ B decoy is an oligonucleotide containing the binding sequence GGGRHTYYHC (where R means A or G, Y means C or T, H means A, C or T) (1) The prevention / treatment / improving agent described in (1).
- the NF- ⁇ decoy is completely in phase with the oligonucleotide represented by SEQ ID NO: 3.
- the preventive / therapeutic / improving agent according to any one of (1) to (5), comprising an oligonucleotide having a complementary sequence.
- NF- ⁇ decoy specifically, for example, an oligonucleotide represented by SEQ ID NO: 3 and an oligonucleotide having a completely complementary sequence described in US6262033 publication A double-stranded oligonucleotide consisting of
- the NF-KB decoy oligonucleotide may be single-stranded or double-stranded, but is preferably double-stranded.
- the phosphate group part may be modified by phosphorothioation or the like.
- NF-CB decoy is not limited, it is preferably administered in the form of fine powder, especially dry powder.
- fine powder especially dry powder.
- the particle size of the fine powder is also not limited, usually about 0.01 ⁇ 50 ⁇ m, is preferably from 0.05 ⁇ 30J (m, more preferably from about 0. l ⁇ 10 m.
- a pharmaceutically acceptable carrier When administered as a fine powder, it is usually formulated as a composition with a pharmaceutically acceptable carrier.
- the carrier is not limited as long as it is used as a pharmaceutical additive, and specific examples thereof include glucose, lactose, trehalose, sucrose, mannitol, and xylitol.
- the administration method is not limited, but specifically, it is administered using a device such as a metered dose inhaler (MDI), a dry powder inhaler (DPI), or a nebulizer.
- MDI metered dose inhaler
- DPI dry powder inhaler
- nebulizer a device such as a metered dose inhaler (MDI), a dry powder inhaler (DPI), or a nebulizer.
- MDI metered dose inhaler
- DPI dry powder inhaler
- Fig. 2 shows the number of inflammatory cells in bronchoalveolar lavage fluid.
- Example 1 Effect of NF-KB decoy on chronic obstructive pulmonary disease model in guinea pigs caused by smoke of octopus
- oligonucleotide consisting of the oligonucleotide represented by SEQ ID NO: 3 and its complementary strand
- NF- ⁇ B decoy oligonucleotide consisting of double-stranded oligonucleotides whose phosphoric acid bonds are phosphorylated
- Two sample beads for multi-bead shocker were prepared, weighed about 2g each of D-mannitol, put a metal cone, and plugged. Next, the sample tube was set in a multi-bead shocker and pulverized under the following conditions.
- NF- ⁇ B decoy powder and mannitol finely powdered by the above method are precisely measured, put into a sample tube for multi-bead shocker, put a metal cone, and then pulverized again under the same conditions as above. (Average particle size of 5 ⁇ m or less).
- the guinea pig respiratory function (special airway resistance, tidal volume, minute ventilation) is awakened by the double flow plethysmograph method. Measured below. Measurements were taken before exposure and the day after the end of exposures 2, 3 and 4 weeks. Respiratory function for 100 breaths was measured for each animal, and the average value was taken as the measured value. The amount of change in respiratory function during each measurement week was calculated using the following formula.
- BALF Bronchoalveolar lavage fluid
- BALF was centrifuged at 230 x g (rotation speed: HOOrpm, rotation radius: 17cm) at 4 ° C for 10 minutes to obtain a precipitate (pellet).
- the pellet was suspended in 0.5 mL of physiological saline.
- the number of cells per 1 / L was calculated after 4 room measurements.
- AMG-10, AMG-50 and AMG-250 represent 10jUg / kg, 50 g / kg and 250 / g / kg of NF-/ ⁇ B decoy dose, respectively.
- the changes in the AMG-10, 50, and 250 treatment groups averaged 0.741, 0.475, and 0.360 cmH 20 xmL / (mL / sec), respectively, at 4 weeks after exposure to cigarette smoke, and the NF- ⁇ ⁇ treatment group was dose-dependent. Increased airway resistance was suppressed.
- the average number of cells in the AMG-10 group is 4605 / ⁇ , and the average number of cells in histocytes, macrophages, neutrophils, eosinophils and lymphocytes is 2088, 373, 1554, 478 and 112 // L, AMG-50 administration group averaged 3580, 1575, 644, 705 518 and 139 / ⁇ , respectively, AMG-250 administration group averaged 2380, 1229, 203, 785 96 and The number was 68 / ⁇ L.
- NF- ⁇ decoy treatment group the total number of cells and histocytes in bronchoalveolar lavage fluid decreased, and in particular, macrophages showed significant suppression in the AMG-10 and 250 treatment groups compared to the control (medium) group. It was. Among the inflammatory cells involved in C0PD, macrophages also occupy an important position, suggesting that NF- / B decoy is effective in improving C0PD symptoms.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006553032A JPWO2006075776A1 (ja) | 2005-01-13 | 2006-01-12 | 慢性閉塞性肺疾患(COPD)、嚢胞性線維症(CysticFibrosis)または肺高血圧症(pulmonaryhypertension)治療剤 |
CA002594675A CA2594675A1 (en) | 2005-01-13 | 2006-01-12 | Therapeutic agent for chronic obstructive pulmonary disease (copd), cystic fibrosis or pulmonary hypertension |
EP06700849A EP1837035A4 (en) | 2005-01-13 | 2006-01-12 | THERAPEUTIC AGENT FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES, CYSTIC FIBROSIS OR PULMONARY HYPERTENSION |
US11/794,167 US20090215868A1 (en) | 2005-01-13 | 2006-01-12 | Therapeutic Medicament for Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and Pulmonary Hypertension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-006893 | 2005-01-13 | ||
JP2005006893 | 2005-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006075776A1 true WO2006075776A1 (ja) | 2006-07-20 |
Family
ID=36677790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/300665 WO2006075776A1 (ja) | 2005-01-13 | 2006-01-12 | 慢性閉塞性肺疾患(COPD)、嚢胞性線維症(Cystic Fibrosis)または肺高血圧症(pulmonary hypertension)治療剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090215868A1 (ja) |
EP (1) | EP1837035A4 (ja) |
JP (1) | JPWO2006075776A1 (ja) |
CA (1) | CA2594675A1 (ja) |
WO (1) | WO2006075776A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010500360A (ja) * | 2006-08-10 | 2010-01-07 | アルボア コーポレーション | 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996035430A1 (fr) * | 1995-05-12 | 1996-11-14 | Fujisawa Pharmaceutical Co., Ltd. | TRAITEMENT ET PREVENTION DE MALADIES ASSOCIEES A NF-λB |
JPH09501057A (ja) * | 1993-11-05 | 1997-02-04 | アイシス・ファーマシューティカルス・インコーポレーテッド | 新規のオリゴヌクレオチド相互作用による血管細胞接着分子の発現の調節 |
JP2002193813A (ja) * | 2000-12-27 | 2002-07-10 | Anges Mg Inc | デコイを含む薬学的組成物およびその使用方法 |
WO2003105780A2 (en) * | 2002-06-18 | 2003-12-24 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
JP2005160464A (ja) * | 2003-12-02 | 2005-06-23 | Corgentech Inc | NF−κBオリゴヌクレオチドデコイ分子 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005004913A1 (ja) * | 2003-07-09 | 2005-01-20 | Anges Mg, Inc. | デコイを含む薬学的組成物およびその使用方法 |
JP2007512845A (ja) * | 2003-12-02 | 2007-05-24 | アネシバ・インコーポレイテッド | Nf−κbオリゴヌクレオチドデコイ分子 |
-
2006
- 2006-01-12 WO PCT/JP2006/300665 patent/WO2006075776A1/ja active Application Filing
- 2006-01-12 US US11/794,167 patent/US20090215868A1/en not_active Abandoned
- 2006-01-12 CA CA002594675A patent/CA2594675A1/en not_active Abandoned
- 2006-01-12 EP EP06700849A patent/EP1837035A4/en not_active Withdrawn
- 2006-01-12 JP JP2006553032A patent/JPWO2006075776A1/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09501057A (ja) * | 1993-11-05 | 1997-02-04 | アイシス・ファーマシューティカルス・インコーポレーテッド | 新規のオリゴヌクレオチド相互作用による血管細胞接着分子の発現の調節 |
WO1996035430A1 (fr) * | 1995-05-12 | 1996-11-14 | Fujisawa Pharmaceutical Co., Ltd. | TRAITEMENT ET PREVENTION DE MALADIES ASSOCIEES A NF-λB |
JP2002193813A (ja) * | 2000-12-27 | 2002-07-10 | Anges Mg Inc | デコイを含む薬学的組成物およびその使用方法 |
WO2003105780A2 (en) * | 2002-06-18 | 2003-12-24 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
JP2005160464A (ja) * | 2003-12-02 | 2005-06-23 | Corgentech Inc | NF−κBオリゴヌクレオチドデコイ分子 |
Non-Patent Citations (4)
Title |
---|
GRIESENBACH U. ET AL.: "Anti-inflammatory gene therapy directed at the airwat epithelium", GENE THERAPY, vol. 7, 2000, pages 306 - 313, XP001041670 * |
See also references of EP1837035A4 * |
WRIGHT J.T. ET AL.: "The Role of Nuclear Factor Kappa B in the Pathogenesis of Pulmonary Diseases: Implications for Therapy", AMERICAN JOURNAL OF RESPIRATORY MEDICINE, vol. 2, no. 3, 2003, pages 211 - 219, XP003000406 * |
YAMAGUCHI T. ET AL.: "Konnichi no Chiryo Shishin", 2004 NENDOBAN, vol. 46, 2004, pages 1530 - 1535, XP003000407 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010500360A (ja) * | 2006-08-10 | 2010-01-07 | アルボア コーポレーション | 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法 |
US8940683B2 (en) | 2006-08-10 | 2015-01-27 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
US10550389B2 (en) | 2006-08-10 | 2020-02-04 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
US11091763B2 (en) | 2006-08-10 | 2021-08-17 | Altavant Sciences Gmbh | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
US11718853B2 (en) | 2006-08-10 | 2023-08-08 | Onspira Therapeutics, Inc. | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CA2594675A1 (en) | 2006-07-20 |
JPWO2006075776A1 (ja) | 2008-06-12 |
EP1837035A1 (en) | 2007-09-26 |
US20090215868A1 (en) | 2009-08-27 |
EP1837035A4 (en) | 2009-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6004233B2 (ja) | ホスホジエステラーゼ阻害剤を含む乾燥粉末製剤 | |
AU2005316687B2 (en) | Compositions and methods for pulmonary conditions | |
CN107847480B (zh) | 呼吸性疾病的治疗 | |
JP2012505262A (ja) | Copd及びその他の肺疾患の治療方法 | |
JP2008540563A (ja) | 肺疾患を処置するためのモノクローナル抗体の霧状化 | |
US20100196285A1 (en) | Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract | |
JP2001505553A (ja) | ウリジン三リン酸および関連化合物で気管支炎を治療する方法 | |
CN106470700A (zh) | 用于治疗copd的噻托溴铵、福莫特罗和布地奈德的组合 | |
US20220409627A1 (en) | Treatment of lower airways disorders | |
WO2006075776A1 (ja) | 慢性閉塞性肺疾患(COPD)、嚢胞性線維症(Cystic Fibrosis)または肺高血圧症(pulmonary hypertension)治療剤 | |
US11931368B2 (en) | Glucocorticoid “nintedanib” particles and their use | |
US20060134009A1 (en) | Low dose corticosteroid powders for inhalation | |
JP2021521280A (ja) | 弾性線維分解を治療するための組成物及び方法 | |
JP5154732B2 (ja) | 薬剤 | |
EP2114407B1 (en) | Use of sodium blockers for an early therapy of obstructive lung diseases | |
US20220168297A1 (en) | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension | |
KR20090130360A (ko) | 섬유모세포 성장인자 2를 유효성분으로 함유하는 천식 및 만성폐쇄성 폐질환 치료 또는 예방을 위한 흡입용 약제학적 조성물 | |
US10155001B2 (en) | RAC1 inhibitors for inducing bronchodilation | |
WO2024062005A1 (en) | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor | |
CN110664819A (zh) | 供吸入的齐墩果酸制剂及其制备方法与医药用途 | |
WO2009028917A1 (en) | Formulation for inhalation comprising fibroblast growth factor-2 as an effective ingredient for treatment or prevention of asthma and/or chronic obstructive pulmonary disease | |
JP2008534608A (ja) | 喘息の処置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006553032 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006700849 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11794167 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2594675 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2006700849 Country of ref document: EP |